- Home
- SLN vs PMTS Comparison
SLN vs PMTS Comparison
Compare SLN & PMTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- PMTS
- Stock Information
- Founded
- SLN 1994
- PMTS 2007
- Country
- SLN United Kingdom
- PMTS United States
- Employees
- SLN N/A
- PMTS N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- PMTS Finance Companies
- Sector
- SLN Health Care
- PMTS Finance
- Exchange
- SLN Nasdaq
- PMTS Nasdaq
- Market Cap
- SLN 281.0M
- PMTS 327.9M
- IPO Year
- SLN N/A
- PMTS 2015
- Fundamental
- Price
- SLN $5.92
- PMTS $23.88
- Analyst Decision
- SLN Buy
- PMTS Strong Buy
- Analyst Count
- SLN 5
- PMTS 4
- Target Price
- SLN $32.60
- PMTS $36.75
- AVG Volume (30 Days)
- SLN 111.7K
- PMTS 52.3K
- Earning Date
- SLN 08-14-2025
- PMTS 08-04-2025
- Dividend Yield
- SLN N/A
- PMTS N/A
- EPS Growth
- SLN N/A
- PMTS 1.33
- EPS
- SLN N/A
- PMTS 1.58
- Revenue
- SLN $27,701,000.00
- PMTS $491,426,000.00
- Revenue This Year
- SLN N/A
- PMTS $14.61
- Revenue Next Year
- SLN N/A
- PMTS $12.49
- P/E Ratio
- SLN N/A
- PMTS $15.01
- Revenue Growth
- SLN N/A
- PMTS 12.81
- 52 Week Low
- SLN $1.97
- PMTS $18.46
- 52 Week High
- SLN $22.47
- PMTS $35.19
- Technical
- Relative Strength Index (RSI)
- SLN 58.35
- PMTS 55.92
- Support Level
- SLN $5.33
- PMTS $22.88
- Resistance Level
- SLN $6.00
- PMTS $24.04
- Average True Range (ATR)
- SLN 0.44
- PMTS 0.58
- MACD
- SLN -0.03
- PMTS 0.18
- Stochastic Oscillator
- SLN 64.07
- PMTS 81.61
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About PMTS CPI Card Group Inc.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.